Investing.com | Author Sam Boughedda
Published Feb 17, 2023 00:16
By Sam Boughedda
Emergent BioSolutions (NYSE:EBS) shares have surged 21% premarket after the company announced Thursday that the US Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee unanimously voted in favor of the benefit-risk profile of NARCAN Nasal Spray.
The committees voted, with a total of 19 votes, that the nasal spray supports its use as a non-prescription opioid overdose reversal agent, although the FDA is not bound by the vote and only considers the committees' advice.
Emergent had previously presented an overview of its over-the-counter development program, the medical need, Human Factors study data, and seven years of post-marketing safety data.
If the FDA approves NARCAN, a prescription medicine used for the emergency treatment of a known or suspected opioid overdose emergency, it would be the first 4 mg naloxone nasal spray available OTC in the US.
Reacting to the announcement, Cowen analysts, who have a Market Perform rating and $25 price target on the stock, said the vote in favor was "largely expected," and they anticipate the approval of OTC Narcan by the March 29, 2023, PDUFA date.
"However, we believe that generic dilution remains the key risk for Narcan and we anticipate significant revenue decline over the next several years," the analysts added.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.